NAFLD in HIV-infected Patients

• Conditions: NAFLD; HIV-infection/Aids

• Registration Number: NCT04215926
• Lead Sponsor: Shanghai Public Health Clinical Center

Brief Summary

The prevalence of NAFLD (nonalcoholic fatty liver disease) in HIV-infected patients is higher than that in general population, but the causes of morbidity and pathogenesis have not been fully explored. The investigators are planning to consecutively enroll 400 cases HIV-positive outpatients, and to detect NAFLD by ultrasound. The fecal and blood samples were also collected to explore the mechanism of NAFLD. The investigators aimed to determine the prevalence and risk factors of NAFLD in HIV infected patients.

Detailed Description

Not available

Study Timeline

• Study Start: 2019-12-05
• Study First Submitted: 2019-12-29
• Study First Submitted QC: 2019-12-29
• Study First Posted: 2020-01-02
• Status Verified: 2020-03
• Last Update Submitted: 2020-03-02
• Last Update Posted: 2020-03-04
• Primary Completion: 2020-10-30
• Study Completion: 2020-11-30

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 400

Inclusion Criteria

• Age 18~70 y;
• HIV-positive patients;
• written the informed consent

Exclusion Criteria

• coinfected with HBV, HCV;
• secondary causes of fatty liver (eg, consumption of amiodarone and tamoxifen) and decompensated liver disease;
• significant alcohol consumption (>20 g per day for man, >10 g per day for woman);
• received antibiotics in preceding two months;
• autoimmune disease;
• severe heart, lung, kidney, brain, blood diseases or other important systemic diseases;
• pregnant or lactating women

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
morbidity of nonalcoholic fatty liver disease	1 month	NAFLD was diagnosed using ultrasound

Trial Locations

Locations (1)

Shanghai Public Health Clinical Center; 🇨🇳 Shanghai, Shanghai, China